Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Jessica Fye - JP Morgan David Amsellem - Piper Sandler Marc Goodman - Leerink Partners. Annabel Samimy - Stifle Joseph Thome - TD Cowen Gregory Renza - RBC Capital Markets Joel Beatty - Baird Ami Fadia - Needham Ashwani Verma - UBS Mohit Bansal - Wells Fargo Gary Nachman - Raymond James Joon Lee - Truist Securities Operator Hello and thank you for standing by.
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51 per share. This compares to earnings of $2.68 per share a year ago.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?
Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
